Kiora Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies aimed at treating rare and complex diseases
The company specializes in advancing drug candidates that utilize unique formulations and targeted delivery mechanisms to improve patient outcomes. Kiora's research and development efforts are centered on addressing unmet medical needs through a combination of proprietary approaches and strategic collaborations. By leveraging cutting-edge technology and scientific expertise, the company strives to bring effective treatments to market for conditions with limited therapeutic options.
Shares of Meta Platforms, Inc. (NASDAQMETA) rose sharply in today’s pre-market trading as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share.
Shares of C.H. Robinson Worldwide, Inc. (NASDAQCHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.
Kiora Pharmaceuticals also entered into a securities purchase agreement with certain institutional investors, pursuant to which Kiora agreed to issue and sell 15,800,000 shares and warrants for expected aggregate gross proceeds at closing of approximately $15 million and potential future warrant exercise gross proceeds of approximately $30 million.
